1229622-07-4

Upstream product

• 1229622-03-0 7-methoxy-2,3,4,5-tetrahydro-1H-benzo[d]azepin-1-ol 
• 15733-63-8 5-chloropentylbenzene 
• 2039-67-0 2-(3-methoxyphenyl)-1-ethanamine 
• 64880-89-3 N-[(3-methoxyphenyl)ethyl]-4′′-methylbenzenesulfonamide 
• 81593-59-1 7-methoxy-3-(4-methylphenylsulfonyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-1-ol 
• 81593-57-9 7-methoxy-3-(4-methylphenylsulfonyl)-2,3,4,5-tetrahydro-3-benzazepin-1-one 
• 81593-56-8 [[2-(3-Methoxy-phenyl)-ethyl]-(toluene-4-sulfonyl)-amino]-acetic acid 

Relevant academic research and scientific papers

NR2B SELECTIVE NMDA-RECEPTOR ANTAGONISTS FOR TREATMENT OF IMMUNE-MEDIATED INFLAMMATORY DISEASES

The present invention provides novel means and methods for treatment auf immunemediated inflammatory diseases.

Design, synthesis, and biological evaluation of 3-benzazepin-1-ols as NR2B-selective NMDA receptor antagonists

Cleavage and reconstitution of a bond in the piperidine ring of ifenprodil (1) leads to 7-methoxy-2,3,4,5-tetrahydro-1H-3-benzazepin-1-ols, a novel class of NR2B-selective NMDA receptor antagonists. The secondary amine 7-methoxy-2,3,4,5-tetrahydro-1H-3-be

NR2B-SELECTIVE NMDA-RECEPTOR ANTAGONISTS

The present invention relates to compounds according to general formula (I) and pharmaceutical compositions comprising compounds according to general formula (I).